Australian life sciences company Bioxyne today announces positive results from its Australian clinical trial into the effects of taking a daily probiotic supplement containing the bacteria strain Lactobacillus fermentum VRI-003, with participants who consumed the […]
Bloom Science and Biose industrie announced today an agreement for the manufacture development of Bloom Science’s novel epilepsy Live Biotherapeutic Product (LBP). Bloom is targeting rare epileptic syndromes with orally-delivered pharmaceutical compositions of specific combined […]
Eagle Genomics joins a specialised group of high-growth startups, earning co-sell status as part of Microsoft’s new programme to collaborate on intensive joint sales and go-to-market initiatives. Eagle Genomics will partner with Microsoft sales teams […]
More than 1,000 species of bacteria have been identified in the human gut, and understanding this incredibly diverse “microbiome” that can greatly impact health and disease is a hot topic in scientific research. Because bacteria […]
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces that it has entered into an agreement with a US company (“The Company”) for the use […]
Nutraceutical Corporation is pleased to announce that Dr. Raphael Kellman, MD will be advising the company in the development and promotion of its Solaray® Mycrobiome® Probiotic line of products. Dr. Kellman is a best-selling author […]
Microbiome-focused companies have many different areas of interest—but what they have in common is a drive to learn more about the conditions and activities of bacteria and other microorganisms. Martha Carlin, CEO and co-founder of […]
Carbiotix, an award winning biotechnology start-up focused on optimizing gut health with soluble fiber (prebiotics), has closed a second pre-seed financing round of 450,000 Euros, bringing the total capital raised to date to 700,000 Euros. Participating in […]
Clalit Health Services, the leading HMO in Israel, and DayTwo are partnering to bring to market a glycemic-control product for people with Type 2 diabetes. The glycemic-control offering is based on the genetic sequencing of […]
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of live biotherapeutics, announces the publication of a paper demonstrating that MRx0004, a live biotherapeutic derived from the human gut microbiome, can protect against […]
Kaleido Biosciences, a clinical-stage healthcare company leading the development of novel chemistries that drive functions of the microbiome organ, today announced that Alison Lawton, Kaleido’s president and chief operating officer (COO), has been appointed to […]